drugset
drugset / Trial / NCT00747344

A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis

NCT00747344 ↗

Phase 3 Completed 121 enrolled Centocor, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Ustekinumab in the treatment of patients with moderate to severe psoriasis in South Korea and Taiwan.

Timeline

Start
2008-12
Primary completion
2009-09
Completion
2010-03

Outcome

Met primary endpoint

registry Placebo vs Ustekinumab 45 mg; p <0.001; Cochran-Mantel-Haenszel NCT00747344 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ustekinumab Monoclonal antibody 45 mg Subcutaneous

Indications

psoriasis